Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Warning Letter Slams Another Asian API Firm On Data Integrity

Executive Summary

Data integrity warning letter to Chinese API maker reflects continuing focus of FDA enforcement efforts on the pharmaceutical industry's Asian supply chain.

You may also be interested in...



FDA Warning Letter Hits US Lab On Data Integrity, Password Sharing

Data integrity lapses raised in FDA warning letter to California analytical testing lab shows that such issues are not confined to Asia and that FDA will, in fact, challenge US facilities to show they are managing their quality data properly.

Data Integrity Lapses Continue To Bedevil Manufacturers

A recent compilation of FDA warning letters shows that data integrity failings continue to plague API and finished drug manufacturing sites in Asia and Europe.

Enforcement Updates in Brief

FDA import alerts hit Chinese firms and Teva; EU GMP suspensions hit Bend Research and several Indian firms.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS118892

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel